Bio-rad Laboratories vs Medpace Holdings
Bio-rad Laboratories and Medpace Holdings are similar in size: $2.58bn and $2.53bn of revenue in their latest fiscal years. Medpace Holdings grew faster (20.0% against 0.7%). Bio-rad Laboratories kept more of each dollar of sales as profit: a net margin of 29.4% against 17.8%. Medpace Holdings carries less debt relative to equity (0.0% against 16.2%).
| Latest fiscal year | Bio-rad LaboratoriesBIO, 2025 | Medpace HoldingsMEDP, 2025 |
|---|---|---|
| Revenue | $2.58bn | $2.53bn |
| Revenue growth | 0.7% | 20.0% |
| Net income | $760m | $451m |
| Operating margin | 1.8% | 21.1% |
| Net margin | 29.4% | 17.8% |
| Return on equity | 10.8% | 70.2% |
| Free cash flow | $375m | $682m |
| Cash | $530m | $497m |
| Total debt | $1.21bn | $0 |
| Debt to equity | 16.2% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $296m | $917m |
| Employees | 7,450 | 6,200 |
| Market value | $10.02bn | $18.66bn |
| Price vs our value range | Above our value range | Below our value range |
| Moat score | 56 (Moderate) | 89 (Strong) |
| Insider trades, 12 months | 0 buys, 2 sales | 0 buys, 56 sales |